Speed
77 days to first decision for reviewed manuscripts only
61 days to first decision for all manuscripts
140 days from submission to acceptance
18 days from acceptance to publication
Citation Impact
4.234 - 2-year Impact Factor
3.972 - 5-year Impact Factor
1.191 - Source Normalized Impact per Paper (SNIP)
1.154 - SCImago Journal Rank (SJR)
Usage
511,811 Downloads
141 Altmetric mentions
The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
Niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for first/second-line maintenance treatment of ovarian cancer patients with complete or partial response to platinum-based chemotherapy, ...
Citation: Journal of Ovarian Research 2021 14:68